CDK18 and neoplasm: In the sub-group that received CMF based chemotherapy, there was a similar trend with better survival in patients with high cytoplasmic CDK18 expressing tumours (p = 0.07; Figure 2E), but not in patients who received anthracycline-based chemotherapy (Figure 2F).